Dr Alan Cameron

  • Honorary Clinical Lecturer (Institute of Cardiovascular & Medical Sciences)

email: Alan.Cameron.2@glasgow.ac.uk

Graduate School Office, Room 362, Wolfson Link Building, G12 8qq

Biography

Degrees

MB ChB, BSc (Hons), MRCP

Current Position

I am an Honorary Clinical Lecturer and Specialty Registrar in Clinical Pharmacology and Medicine at the University of Glasgow and NHS Greater Glasgow and Clyde. 

Background

I graduated in Medicine from the University of Glasgow in 2010 and achieved an Intercalated BSc in Cardiovascular Medicine with First Class Honours in 2008.  I completed early clinical academic training as part of the Glasgow Academic Training Environment (GATE) from 2010 to 2014, and a Clinical Teaching Fellowship in Medicine with Postgraduate Certificate in Health Professions Education (Merit) at the Western Infirmary Glasgow from 2014-15.  I commenced a BHF Centre of Research Excellence PhD Fellowship at the University of Glasgow Institute of Cardiovascular and Medical Sciences in 2015 and I am currently an Honorary Clinical Lecturer and Specialty Registrar in Clinical Pharmacology and Medicine. 

Research interests

Cardiovascular Complications of Chemotherapy

I play a fundamental role in a programme of novel and innovative translational cardio-oncology studies, focussing on the cardiovascular effects of cisplatin and VEGF inhibitor chemotherapy.  Our research aims to successfully unravel the mechanisms whereby chemotherapy drugs cause vascular damage and identify approaches to maintain vascular health and prevent cardiovascular disease in patients treated with chemotherapy drugs that induce cardiovascular toxicity.

Stroke Medicine

I play an active role in research studies that aim to reduce the burden of stroke by improving approaches to primary and secondary prevention, as well as optimising the management of patients with acute stroke, including intravenous thrombolysis. 

Presentations

Oral Presentations

Cameron AC, Delles C, Lang NN, Touyz RM. Masked Hypertension Contributing to Severe Hypertensive Heart Disease with Left Ventricular Outflow Tract Obstruction. American Heart Association’s Hypertension Scientific Sessions 2018.

Cameron AC, Abdul-Rahim AH, Bogie J, et al. Alteplase Dose for Acute Ischaemic Stroke:
Higher Absolute Doses are Associated with Favourable Functional Outcomes and Survival. 4th European Stroke Organisation Conference 2018.

Cameron AC, Bogie J, Abdul-Rahim AH, et al. Professional guideline versus product licence selection for treatment with IV thrombolysis: compliance with product licences is highest in lower efficiency sites and restricts thrombolysis usage. 3rd European Stroke Organisation Conference 2017.

Cameron AC, Hall M, Rios F, et al. Vascular effects of cisplatin-based chemotherapy for testicular cancer (VECTOR) study. Global Cardio-Oncology Summit 2017.

Cameron AC, Lees KR, Booth MG, et al. A survey of principal researchers who lead research into Adults with Incapacity in Scotland. 10th Congress of the European Association for Clinical Pharmacology and Therapeutics 2011.

Poster Presentations

Cameron AC, Welsh P, Touyz RM, Lang NN. Vascular effects of VEGF inhibition with bevacizumab in-vivo in man. British Pharmacological Society Annual Meeting 2018.

Cameron AC, Hall M, Rios F, Waterston A, White J, Youyz RM, Lang NN. Vascular effects of anti-cancer cisplatin therapy. 28th European Meeting on Hypertension and Cardiovascular Protection / European Society of Hypertension 2018.

Cameron AC, Chaudry F, Elliot E, Dawson J. Improving Cardiovascular Risk Factor Screening in Acute Stroke. Royal College of Physicians of Edinburgh Stroke Symposium 2018.

Cameron AC, Neves KB, Rios FJ, et al. Vascular endothelial growth factor inhibitors (VEGFI) induce endothelial cell activation in cancer patients. Global Cardio-Oncology Summit 2017.

Cameron AC, Neves KB, Rios FJ, Montezano AC, White J, Lang NN, Touyz RM. Molecular mechanisms underlying the vascular effects of cisplatin. Global Cardio-Oncology Summit 2017

Cameron AC, McCallum L, Gardiner T, et al. An audit of appropriate use of antithrombotic therapy in patients presenting with suspected acute coronary syndrome. 3rd International Triennial Conference of the Royal College of Physicians and Surgeons of Glasgow, 2014.

Cameron AC, Jenkins SMM, Sonecki P. Stress echocardiography in a University teaching hospital – a retrospective analysis. 7th International Conference of the Society for Acute Medicine, 2013.

Cameron AC, Dawson J, Quinn TJ, Lim WH, Walters MR. Dipyridamole therapy after stroke: adverse effects are common. 10th Congress of the European Association for Clinical Pharmacology and Therapeutics. Basic Clin Pharmacol Toxicol. 2011;109(s1):77.

Gallanagh S, Cameron AC, Walters MR. Thrombolysis for acute ischaemic stroke: a prospective analysis of resource challenges associated with providing a regional service. 10th Congress of the European Association for Clinical Pharmacology and Therapeutics. Basic Clin Pharmacol Toxicol. 2011;109(s1):99.

Dawson J, Cameron AC, Walters MW, et al. Neurological morbidity and mortality following attendance at a transient ischaemic attack clinic. International Stroke Conference, 2011. Stroke. 2011;42:e250.

Lim WY, Cameron AC, Dawson J, et al. Variation in the delivery of stroke unit care in Scottish hospitals: an interview-based survey and analysis. Scottish Society of Physicians Annual Meeting 2010. Scott Med J. 2011;56:49.

Cameron AC, Dawson J, Quinn TJ, et al. Permanent pacemaker insertion following attendance at a transient ischaemic attack clinic. 6th World Stroke Congress. Int. J. Stroke. 2008;3(s1):84.

Cameron AC, Dawson J, Quinn TJ, et al. Long-term outcome following attendance at a transient ischaemic attack clinic. 6th World Stroke Congress. Int. J. Stroke. 2008;3(s1):404.

Quinn TJ, Cameron AC, Dawson J, et al. ABCD2 score as a predictor of non-cerebrovascular diagnoses. 17th European Stroke Congress. Cerebrovasc. Dis. 2008;25(s2):169,2015

 

Publications

List by: Type | Date

Jump to: 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015
Number of items: 19.

2021

Cameron, A. C., Neves, K. B. , White, J., Touyz, R. M. and Lang, N. N. (2021) Reply: Cisplatin-associated aortic thrombosis: a review of cases reported to the FDA adverse event reporting system. JACC: CardioOncology, 3(1), p. 166. (doi: 10.1016/j.jaccao.2021.01.005)

Gill, D. et al. (2021) Urate, blood pressure, and cardiovascular disease: evidence from Mendelian randomization and meta-analysis of clinical trials. Hypertension, 77(2), pp. 383-392. (doi: 10.1161/HYPERTENSIONAHA.120.16547) (PMID:33356394) (PMCID:PMC7803439)

2020

Steinthorsdottir, V. et al. (2020) Genetic predisposition to hypertension is associated with preeclampsia in European and Central Asian women. Nature Communications, 11, 5976. (doi: 10.1038/s41467-020-19733-6) (PMID:33239696) (PMCID:PMC7688949)

Cameron, A. C. et al. (2020) Comprehensive characterisation of the vascular effects of cisplatin-based chemotherapy in patients with testicular cancer. JACC: CardioOncology, 2(3), pp. 443-455. (doi: 10.1016/j.jaccao.2020.06.004) (PMID:33043304) (PMCID:PMC7539369)

Yu, W. M., Abdul-Rahim, A. , Cameron, A., Kõrv, J., Sevcik, P., Toni, D. and Lees, K. (2020) The incidence and associated factors of early neurological deterioration after thrombolysis: Results from SITS Registry. Stroke, 51(9), pp. 2705-2714. (doi: 10.1161/STROKEAHA.119.028287) (PMID:32811373)

Mentel, A., Quinn, T. J. , Cameron, A. C., Lees, K. R. and Abdul-Rahim, A. H. (2020) The impact of atrial fibrillation type on the risks of thromboembolic recurrence, mortality and major haemorrhage in patients with previous stroke: a systematic review and meta-analysis of observational studies. European Stroke Journal, 5(2), pp. 155-168. (doi: 10.1177/2396987319896674) (PMID:32637649) (PMCID:32637649)

Cameron, A. C., Welsh, P. , Neves, K. B. , Newby, D., Touyz, R. M. and Lang, N. (2020) Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation. Journal of Hypertension, 38(2), pp. 257-265. (doi: 10.1097/HJH.0000000000002230) (PMID:31449168) (PMCID:PMC7197298)

2019

Cameron, A. C. et al. (2019) Progressive hypertension and severe left ventricular outflow tract obstruction. Hypertension, 74(6), pp. 1216-1225. (doi: 10.1161/hypertensionaha.119.13343) (PMID:31587571)

Sharma, V. et al. (2019) Report from the Annual Conference of the British Society of Echocardiography, November 2017, Edinburgh International Conference Centre, Edinburgh. Echo Research and Practice, 6(4), M1-M2. (doi: 10.1530/ERP-19-0056)

Cameron, A.C., Dominiczak, A.F. and Touyz, R.M. (2019) Hypertension. In: Touyz, R.M. and Delles, C. (eds.) Textbook of Vascular Medicine. Springer Nature Switzerland: Cham, Switzerland, pp. 331-341. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_31)

Cameron, A. C., Rossitto, G., Lang, N. N. and Touyz, R. M. (2019) Antihypertensive drugs and vascular health. In: Zimlichman, R., Julius, S. and Mancia, G. (eds.) Prehypertension and Cardiometabolic Syndrome. Series: Updates in hypertension and cardiovascular protection. Springer, pp. 585-605. ISBN 9783319753096 (doi: 10.1007/978-3-319-75310-2_37)

Cameron, A. C., Touyz, R. M. and Lang, N. N. (2019) Vascular biology of cancer chemotherapeutic drugs. In: Touyz, R. M. and Delles, C. (eds.) Textbook of Vascular Medicine. Springer: Cham, pp. 259-268. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_24)

2018

Dobbin, S. J.H. , Cameron, A. C., Petrie, M. C. , Jones, R. J. , Touyz, R. M. and Lang, N. N. (2018) Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart, 104(24), pp. 1995-2002. (doi: 10.1136/heartjnl-2018-313726) (PMID:30228246) (PMCID:PMC6268130)

Neves, K. B. , Rios, F. J. , Van Der Mey, L., Alves-Lopes, R. , Cameron, A. C., Volpe, M., Montezano, A. C., Savoia, C. and Touyz, R. M. (2018) VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes. Hypertension, 71(4), pp. 638-647. (doi: 10.1161/HYPERTENSIONAHA.117.10490) (PMID:29483228)

Cameron, A. C., Bogie, J., Abdul-Rahim, A. H. , Ahmed, N., Mazya, M., Mikulik, R., Hacke, W. and Lees, K. R. (2018) Professional guideline versus product label selection for treatment with IV thrombolysis: an analysis from SITS registry. European Stroke Journal, 3(1), pp. 39-46. (doi: 10.1177/2396987317747737)

2017

Cameron, A. C., Lang, N. N. and Touyz, R. M. (2017) Cardiovascular complications from cancer therapy: hypertension-focus on vascular endothelial growth factor inhibitors. In: Herrmann, J. (ed.) Clinical Cardio-oncology. Elesvier: Amsterdam, pp. 185-211. ISBN 9780323442275 (doi: 10.1016/B978-0-323-44227-5.00010-7)

2016

Cameron, A. C., Lang, N. N. and Touyz, R. M. (2016) Drug treatment of hypertension: focus on vascular health. Drugs, 76(16), pp. 1529-1550. (doi: 10.1007/s40265-016-0642-8) (PMID:27667708)

2015

Cameron, A. C., Touyz, R. M. and Lang, N. N. (2015) Vascular complications of cancer chemotherapy. Canadian Journal of Cardiology, 32(7), pp. 852-862. (doi: 10.1016/j.cjca.2015.12.023) (PMID:26968393) (PMCID:PMC4989034)

Cameron, A. C., Mccallum, L., Gardiner, T., Darroch, C., Walters, M. R. and Oldroyd, K. G. (2015) Impact of treatment algorithms on the prescribing of antithrombotic therapy in patients with suspected acute coronary syndrome - a prospective audit. British Journal of Clinical Pharmacology, 80(5), pp. 1176-1184. (doi: 10.1111/bcp.12714) (PMID:26147691)

This list was generated on Mon Dec 6 17:03:01 2021 GMT.
Number of items: 19.

Articles

Cameron, A. C., Neves, K. B. , White, J., Touyz, R. M. and Lang, N. N. (2021) Reply: Cisplatin-associated aortic thrombosis: a review of cases reported to the FDA adverse event reporting system. JACC: CardioOncology, 3(1), p. 166. (doi: 10.1016/j.jaccao.2021.01.005)

Gill, D. et al. (2021) Urate, blood pressure, and cardiovascular disease: evidence from Mendelian randomization and meta-analysis of clinical trials. Hypertension, 77(2), pp. 383-392. (doi: 10.1161/HYPERTENSIONAHA.120.16547) (PMID:33356394) (PMCID:PMC7803439)

Steinthorsdottir, V. et al. (2020) Genetic predisposition to hypertension is associated with preeclampsia in European and Central Asian women. Nature Communications, 11, 5976. (doi: 10.1038/s41467-020-19733-6) (PMID:33239696) (PMCID:PMC7688949)

Cameron, A. C. et al. (2020) Comprehensive characterisation of the vascular effects of cisplatin-based chemotherapy in patients with testicular cancer. JACC: CardioOncology, 2(3), pp. 443-455. (doi: 10.1016/j.jaccao.2020.06.004) (PMID:33043304) (PMCID:PMC7539369)

Yu, W. M., Abdul-Rahim, A. , Cameron, A., Kõrv, J., Sevcik, P., Toni, D. and Lees, K. (2020) The incidence and associated factors of early neurological deterioration after thrombolysis: Results from SITS Registry. Stroke, 51(9), pp. 2705-2714. (doi: 10.1161/STROKEAHA.119.028287) (PMID:32811373)

Mentel, A., Quinn, T. J. , Cameron, A. C., Lees, K. R. and Abdul-Rahim, A. H. (2020) The impact of atrial fibrillation type on the risks of thromboembolic recurrence, mortality and major haemorrhage in patients with previous stroke: a systematic review and meta-analysis of observational studies. European Stroke Journal, 5(2), pp. 155-168. (doi: 10.1177/2396987319896674) (PMID:32637649) (PMCID:32637649)

Cameron, A. C., Welsh, P. , Neves, K. B. , Newby, D., Touyz, R. M. and Lang, N. (2020) Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation. Journal of Hypertension, 38(2), pp. 257-265. (doi: 10.1097/HJH.0000000000002230) (PMID:31449168) (PMCID:PMC7197298)

Cameron, A. C. et al. (2019) Progressive hypertension and severe left ventricular outflow tract obstruction. Hypertension, 74(6), pp. 1216-1225. (doi: 10.1161/hypertensionaha.119.13343) (PMID:31587571)

Sharma, V. et al. (2019) Report from the Annual Conference of the British Society of Echocardiography, November 2017, Edinburgh International Conference Centre, Edinburgh. Echo Research and Practice, 6(4), M1-M2. (doi: 10.1530/ERP-19-0056)

Dobbin, S. J.H. , Cameron, A. C., Petrie, M. C. , Jones, R. J. , Touyz, R. M. and Lang, N. N. (2018) Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart, 104(24), pp. 1995-2002. (doi: 10.1136/heartjnl-2018-313726) (PMID:30228246) (PMCID:PMC6268130)

Neves, K. B. , Rios, F. J. , Van Der Mey, L., Alves-Lopes, R. , Cameron, A. C., Volpe, M., Montezano, A. C., Savoia, C. and Touyz, R. M. (2018) VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes. Hypertension, 71(4), pp. 638-647. (doi: 10.1161/HYPERTENSIONAHA.117.10490) (PMID:29483228)

Cameron, A. C., Bogie, J., Abdul-Rahim, A. H. , Ahmed, N., Mazya, M., Mikulik, R., Hacke, W. and Lees, K. R. (2018) Professional guideline versus product label selection for treatment with IV thrombolysis: an analysis from SITS registry. European Stroke Journal, 3(1), pp. 39-46. (doi: 10.1177/2396987317747737)

Cameron, A. C., Lang, N. N. and Touyz, R. M. (2016) Drug treatment of hypertension: focus on vascular health. Drugs, 76(16), pp. 1529-1550. (doi: 10.1007/s40265-016-0642-8) (PMID:27667708)

Cameron, A. C., Touyz, R. M. and Lang, N. N. (2015) Vascular complications of cancer chemotherapy. Canadian Journal of Cardiology, 32(7), pp. 852-862. (doi: 10.1016/j.cjca.2015.12.023) (PMID:26968393) (PMCID:PMC4989034)

Cameron, A. C., Mccallum, L., Gardiner, T., Darroch, C., Walters, M. R. and Oldroyd, K. G. (2015) Impact of treatment algorithms on the prescribing of antithrombotic therapy in patients with suspected acute coronary syndrome - a prospective audit. British Journal of Clinical Pharmacology, 80(5), pp. 1176-1184. (doi: 10.1111/bcp.12714) (PMID:26147691)

Book Sections

Cameron, A.C., Dominiczak, A.F. and Touyz, R.M. (2019) Hypertension. In: Touyz, R.M. and Delles, C. (eds.) Textbook of Vascular Medicine. Springer Nature Switzerland: Cham, Switzerland, pp. 331-341. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_31)

Cameron, A. C., Rossitto, G., Lang, N. N. and Touyz, R. M. (2019) Antihypertensive drugs and vascular health. In: Zimlichman, R., Julius, S. and Mancia, G. (eds.) Prehypertension and Cardiometabolic Syndrome. Series: Updates in hypertension and cardiovascular protection. Springer, pp. 585-605. ISBN 9783319753096 (doi: 10.1007/978-3-319-75310-2_37)

Cameron, A. C., Touyz, R. M. and Lang, N. N. (2019) Vascular biology of cancer chemotherapeutic drugs. In: Touyz, R. M. and Delles, C. (eds.) Textbook of Vascular Medicine. Springer: Cham, pp. 259-268. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_24)

Cameron, A. C., Lang, N. N. and Touyz, R. M. (2017) Cardiovascular complications from cancer therapy: hypertension-focus on vascular endothelial growth factor inhibitors. In: Herrmann, J. (ed.) Clinical Cardio-oncology. Elesvier: Amsterdam, pp. 185-211. ISBN 9780323442275 (doi: 10.1016/B978-0-323-44227-5.00010-7)

This list was generated on Mon Dec 6 17:03:01 2021 GMT.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Preventing Recurrent Cardioembolic Stroke ¿ Right Approach, Right Patient
    Mason Medical Research Foundation
    2021 - 2023
     
  • Preventing Recurrent Cardioembolic Stroke ¿ Right Approach, Right Patient
    Royal College of Physicians and Surgeons of Glasgow
    2021 - 2023
     
  • Preventing Recurrent Cardioembolic Stroke¿
    NHS Greater Glasgow and Clyde Endowment Funds
    2021 - 2023
     
  • Cancer Chemotherapeutics and the Vasculature - Endothelial Effects of VEGF Inhibitorsion In Vivo in Man
    Chief Scientist Office
    2016 - 2018
     
  • Intermediate and Long Term Vascular Effects of Cisplatin in Patients with Testicular Cancer (INTELLECT)
    Mason Medical Research Foundation
    2016 - 2018